NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) today recommended approval of olaparib (AstraZeneca/Merck's Lynparza) for the maintenance treatment of adult patients with germline BRCA1/2 mutations with metastatic pancreatic cancer who are responding to first-line platinum chemotherapy.